Orbcel-C ( DrugBank: Orbcel-C )
2 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 94 | Primary sclerosing cholangitis | 1 |
| 95 | Autoimmune hepatitis | 1 |
94. Primary sclerosing cholangitis
Clinical trials : 148 / Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02997878 (ClinicalTrials.gov) | December 7, 2018 | 13/12/2016 | Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH | An Adaptive, Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis | Cholangitis, Sclerosing;Hepatitis, Autoimmune | Biological: Orbcel-C | University of Birmingham | NHS Blood and Transplant | Recruiting | 18 Years | N/A | All | 18 | Phase 1/Phase 2 | United Kingdom |
95. Autoimmune hepatitis
Clinical trials : 52 / Drugs : 68 - (DrugBank : 27) / Drug target genes : 18 - Drug target pathways : 111
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02997878 (ClinicalTrials.gov) | December 7, 2018 | 13/12/2016 | Selected Mesenchymal Stromal Cells to Reduce Inflammation in Patients With PSC and AIH | An Adaptive, Multicentre, Phase IIa, Multi-disease Trial Investigating the Safety & Activity of a Single Infusion of Selected Mesenchymal Stromal Cells in the Treatment of Patients With Primary Sclerosing Cholangitis & Autoimmune Hepatitis | Cholangitis, Sclerosing;Hepatitis, Autoimmune | Biological: Orbcel-C | University of Birmingham | NHS Blood and Transplant | Recruiting | 18 Years | N/A | All | 18 | Phase 1/Phase 2 | United Kingdom |